Policy & Regulation
Tolero Pharmaceuticals doses first patient with P-1287 for treatment of advanced solid tumors
11 January 2019 -

Novel therapeutics company Tolero Pharmaceuticals Inc reported on Thursday the start of treatment of the first patient with advanced solid tumor with the investigational agent TP-1287 under its Phase 1 study in the US.

The company added TP-1287 is an investigational oral cyclin-dependent kinase 9 (CDK9) inhibitor entering into a Phase 1 study in patients with advanced solid tumours (NCT03604783). TP-1287 has shown favourable oral bioavailability in preclinical models.

This open-label, dose-escalation, safety, pharmacokinetics, and pharmacodynamic study will evaluate the maximum tolerated dose and dose-limiting toxicities of TP-1287 administered in patients with advanced solid tumours,revealed the company.

According to the company, the primary objective of the Phase 1 study is to determine the maximum tolerated dose and dose-limiting toxicities of oral TP-1287 administration in patients with advanced solid tumours.

Login
Username:

Password:


Related Headlines